Skip to main content


Cost-Effectiveness Research

KTE-X19 is a potentially cost-effective alternative to the current standard of care for relapsed/refractory MCL.
Older patients with MCL have a high rate of comorbidities impacting treatment choices and OS.
Positive MRD status after induction and consolidation treatments for patients with MCL is associated with worse PFS and…
Results from a retrospective study show similar outcomes between patients with MCL treated with ibrutinib in the…
A comprehensive review of economic and HRQoL evidence reveals the substantial burden associated with MCL and the…
FACT-8D, a novel health utility measure, may offer an alternative method to generate utilities for the cost-…
A retrospective, population-based study compared the long-term outcomes of patients with MCL who were treated with four…
Recent research suggests cytologic and genetic alteration factors that are significant drivers of progressive disease…
A retrospective study presented at the ASCO Annual Meeting by the North American MCL Consortium provides clinical and…
An alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly…
Back to Top